[

bharat biotech

]

Additional information sought: MoS health informs Parliament on Covaxin for kids

  • In October, Covaxin received the Drugs Controller General of India (DCGI) expert panel’s nod for emergency use authorisation in children aged two to 18. An official claimed at the time that the India-made vaccine’s efficacy in children has been found to be similar to that in adults.
Bharat Biotech's Covaxin received the emergency use listing (EUL) from the World Health Organisation (WHO) on November 3.(Sanchit Khanna/HT PHOTO)
Bharat Biotech's Covaxin received the emergency use listing (EUL) from the World Health Organisation (WHO) on November 3.(Sanchit Khanna/HT PHOTO)
Updated on Nov 30, 2021 10:12 PM IST
Copy Link
Written by Sharangee Dutta | Edited by Avik Roy, Hindustan Times, New Delhi

‘An evidence of effectiveness’: Bharat Biotech on real-world study of Covaxin

The assessment found the vaccine to be 50% effective against Covid-19. Bharat Biotech said earlier this year that the jab was 77.8% effective.
Image used only for representative purpose (PTI)
Image used only for representative purpose (PTI)
Published on Nov 25, 2021 09:26 AM IST
Copy Link
ByHindustan Times, New Delhi

Covaxin 50% effective against Delta variant: Real-world study

The findings are based on the study conducted between April 15 and May 15, at the height of India’s second wave of infections this year. Covaxin in clinical trials had an estimated efficacy of 65% when the more infectious Delta variant was taken into account.
Covaxin in clinical trials had an estimated efficacy of 65% when the more infectious Delta variant was taken into account. (Agencies)
Covaxin in clinical trials had an estimated efficacy of 65% when the more infectious Delta variant was taken into account. (Agencies)
Updated on Nov 25, 2021 06:15 AM IST
Copy Link
ByRhythma Kaul, Hindustan Times, New Delhi

How ‘monkey business’ for Covaxin trial was accomplished near Nagpur

The Rhesus macaque monkeys, used worldwide in medical research, are believed to be the best non-human primates for such studies.
The National Institute of Virology (NIV) researchers contacted multiple zoos and institutes all over India to find some without any luck.(AP)
The National Institute of Virology (NIV) researchers contacted multiple zoos and institutes all over India to find some without any luck.(AP)
Published on Nov 14, 2021 07:45 PM IST
Copy Link
PTI |

News updates from HT: BSF fatally shoots 2 alleged Bangladeshi cattle smugglers 

Here are today’s top news, analysis, and opinion at 1pm. Know all about the latest news and other news updates from Hindustan Times.
BSF guards at the Indo-Bangladesh border in Nadia, West Bengal (File Photo)
BSF guards at the Indo-Bangladesh border in Nadia, West Bengal (File Photo)
Published on Nov 12, 2021 12:53 PM IST
Copy Link
Byhindustantimes.com, New Delhi, Hindustan Times

Lancet publication marks safety and efficacy of Covaxin, says Bharat Biotech

The Hyderabad-based firm further said that it was committed to data transparency.
Bharat Biotech's Covaxin (Sanchit Khanna/HT PHOTO)
Bharat Biotech's Covaxin (Sanchit Khanna/HT PHOTO)
Published on Nov 12, 2021 11:05 AM IST
Copy Link
Byhindustantimes.com, New Delhi

Wait for Covaxin's Covid-19 jab for children gets longer

Bharat Biotech's Covaxin received emergency approval for children in 2-18 age group last month, and is awaiting decision on its inclusion in the national vaccination programme. 
Bharat Biotech said in an official statement earlier that they are waiting for further approvals from the drug regulators. (File photo)
Bharat Biotech said in an official statement earlier that they are waiting for further approvals from the drug regulators. (File photo)
Published on Nov 08, 2021 07:14 PM IST
Copy Link
Byhindustantimes.com, New Delhi

Covaxin approval requested in US for ages 2-18 by Bharat Biotech's partner

Pfizer's shot is the only one approved in the United States for children under the age of 18. The CEO of Ocugen, Bharat Biotech's partner in the US, said if approved, it will give another option to the parents who want to get their young ones inoculated.
Covaxin, developed in India by Bharat Biotech, gained emergency approval from the World Health Organization last week.(HT Photo)
Covaxin, developed in India by Bharat Biotech, gained emergency approval from the World Health Organization last week.(HT Photo)
Published on Nov 06, 2021 09:37 AM IST
Copy Link
Byhindustantimes.com, Hindustan Times, New Delhi

After WHO nod, travellers vaccinated with Covaxin allowed to enter US from Nov 8

The US Centers for Disease Control had on Wednesday acknowledged the WHO's granting of emergency use listing (EUL) to India's indigenous vaccine, which has been developed by Bharat Biotech.
The World Health Organization gave emergency use listing to Covaxin on Wednesday.(Reuters File Photo)
The World Health Organization gave emergency use listing to Covaxin on Wednesday.(Reuters File Photo)
Published on Nov 04, 2021 07:57 AM IST
Copy Link
Byhindustantimes.com | Written by Amit Chaturvedi, Hindustan Times, New Delhi

Momentous occasion for Indian science: Bharat Biotech MD on WHO nod of Covaxin

Bharat Biotech MD Krishna Ella thanked Prime Minister Narendra Modi and all the people of the country who got inoculated with Covaxin shots to “instill confidence in Indian science.”
Bharat Biotech chairman and managing director Krishna Ella also thanked Union health minister Mansukh Mandaviya and all officials of the ministry for their “hardwork” after Covaxin received the WHO nod for emergency use.(MINT_PRINT)
Bharat Biotech chairman and managing director Krishna Ella also thanked Union health minister Mansukh Mandaviya and all officials of the ministry for their “hardwork” after Covaxin received the WHO nod for emergency use.(MINT_PRINT)
Published on Nov 04, 2021 12:04 AM IST
Copy Link
Written by Sharangee Dutta | Edited by Poulomi Ghosh, Hindustan Times, New Delhi

'Diwali of Aatmanirbhar Bharat': Health minister hails PM for Covaxin's WHO nod

"This is a sign of capable leadership. This is the story of Modiji's resolution. This is the language of the faith of Indians. This is the Diwali of a self-reliant India," the health minister wrote thanking WHO for granting emergency use listing to Made-in-India Covaxin.
Bharat Biotech's Covaxin becomes India's first indigenous Covid-19 vaccine to get WHO approval. 
Bharat Biotech's Covaxin becomes India's first indigenous Covid-19 vaccine to get WHO approval. 
Published on Nov 03, 2021 06:53 PM IST
Copy Link
Byhindustantimes.com | Written by Poulomi Ghosh

Covaxin gets WHO approval for emergency use listing

Bharat Biotech's Covaxin is now an internationally approved vaccine against Covid-19 which can be administered to people above the age of 18 years. World Health Organization has however not yet recommended it for pregnant women. 
Bharat Biotech's Covaxin in now a WHO-approved vaccine against Covid-19. 
Bharat Biotech's Covaxin in now a WHO-approved vaccine against Covid-19. 
Published on Nov 03, 2021 05:12 PM IST
Copy Link
Byhindustantimes.com | Written by Poulomi Ghosh

Covaxin's shelf life extended to 12 months, announces Bharat Biotech

The present shelf life considered for Bharat Biotech's Covaxin is six months which means vaccines unused after six months from the date of manufacture go to waste. Now the regulator has approved extending the shelf life to a year. 
Bharat Biotech said the stakeholders have been informed about the announcement that now Covaxin doses are good for use till one year from the date of manufacture. 
Bharat Biotech said the stakeholders have been informed about the announcement that now Covaxin doses are good for use till one year from the date of manufacture. 
Published on Nov 03, 2021 04:36 PM IST
Copy Link
Byhindustantimes.com | Written by Poulomi Ghosh

Guyana recognises Covaxin; Indian high commission hails ‘important step’

In recent days, countries such as Australia and Oman have approved India's first indigenous vaccine against Covid-19.
Vials of Bharat Biotech's Covaxin Covid-19 vaccine (HT File Photo)
Vials of Bharat Biotech's Covaxin Covid-19 vaccine (HT File Photo)
Published on Nov 02, 2021 12:23 PM IST
Copy Link
Byhindustantimes.com, New Delhi

News updates from HT: Australia to recognise Covaxin and all the latest news

Here are today’s top news, analysis, and opinion at 1pm. Know all about the latest news and other news updates from Hindustan Times.
Covaxin (File Photo)
Covaxin (File Photo)
Published on Nov 01, 2021 12:57 PM IST
Copy Link
Byhindustantimes.com, New Delhi, Hindustan Times

US firm eyes trials for Bharat Biotech’s Covaxin but delay in EUL a concern

  • Bharat Biotech itself seems stuck in a regulatory loop, with WHO on Tuesday missing another deadline for the grant of emergency use listing
Earlier, a decision on Covaxin EUL was expected on October 5, after WHO representatives sought additional information on September 27. (HT PHOTO)
Earlier, a decision on Covaxin EUL was expected on October 5, after WHO representatives sought additional information on September 27. (HT PHOTO)
Updated on Oct 30, 2021 02:35 AM IST
Copy Link
ByRhythma Kaul, New Delhi

‘Centre following discussions in WHO’: Foreign secy Shringla on nod for Covaxin

The government was hopeful that the WHO would give its approval very soon, the foreign secretary said.
Bharat Biotech's Covaxin (File Photo)
Bharat Biotech's Covaxin (File Photo)
Published on Oct 28, 2021 05:56 PM IST
Copy Link
Byhindustantimes.com, New Delhi

Oman adds Covaxin to approved list of Covid-19 vaccines

With this, Indians flying to Oman will not have to undergo quarantine upon arrival as the Astrazeneca/Covishield jab is already on the country's list of approved vaccines, the Indian embassy informed.
Covaxin (File Photo)
Covaxin (File Photo)
Published on Oct 27, 2021 06:57 PM IST
Copy Link
Byhindustantimes.com, New Delhi

Covaxin may get approval within 24 hours, says WHO official

Last Friday, speaking on the Covaxin issue, a top official of the WHO said the process of thoroughly evaluating a vaccine for use and recommending it sometimes takes a long time but it has to be ensured that the right advice is given to the world.
Covaxin manufacturer Bharat Biotech submitted data for the emergency use approval in April.(HT Photo)
Covaxin manufacturer Bharat Biotech submitted data for the emergency use approval in April.(HT Photo)
Published on Oct 26, 2021 04:16 PM IST
Copy Link
Byhindustantimes.com | Written by Amit Chaturvedi, Hindustan Times, New Delhi

WHO to consider Covaxin's emergency listing in meet today

WHO has said it “cannot cut corners” to recommend Covaxin’s inclusion in the EUL for vaccination against Covid-19. The agency said last week it was expecting one additional piece of information from the Covaxin manufacturer, which has been submitting data on a rolling basis.
A health worker prepares a dose of the Covaxin Covid-19 vaccine at a vaccination center set up at a Delhi government health dispensary in New Delhi, India. (Bloomberg)
A health worker prepares a dose of the Covaxin Covid-19 vaccine at a vaccination center set up at a Delhi government health dispensary in New Delhi, India. (Bloomberg)
Published on Oct 26, 2021 05:31 AM IST
Copy Link
Written by Joydeep Bose | Edited by Meenakshi Ray, Hindustan Times, New Delhi

‘Phase 2 trials almost completed’: Dr Krishna Ella on nasal Covid-19 vaccine

The vaccine has shown ‘good results,’ the Bharat Biotech chairman and MD said, echoing Dr VK Paul's remarks from last month.
A health worker collects swab samples for Covid-19 tests in Nagpur, Maharashtra. (PTI)
A health worker collects swab samples for Covid-19 tests in Nagpur, Maharashtra. (PTI)
Published on Oct 23, 2021 04:06 PM IST
Copy Link
Byhindustantimes.com, New Delhi

'Cannot cut corners': WHO says awaiting additional information on Covaxin

  • While the decision has been delayed multiple times, Bharat Biotech has maintained that it doesn’t find it “appropriate to speculate or comment on approval process and its timelines.”
The WHO’s nod for Covaxin’s emergency use authorisation is necessary for its widespread acceptability as a safe and effective vaccine.
The WHO’s nod for Covaxin’s emergency use authorisation is necessary for its widespread acceptability as a safe and effective vaccine.
Published on Oct 18, 2021 08:26 PM IST
Copy Link
Byhindustantimes.com | Written by Kunal Gaurav

WHO to meet on Oct 26 to consider Covaxin's emergency listing

  • With this recent development, India can now expect the Emergency Use approval for Covaxin by the last week of October.
On October 5, the world health body extended giving the EUL to Covaxin by a week. (File photo)
On October 5, the world health body extended giving the EUL to Covaxin by a week. (File photo)
Updated on Oct 17, 2021 10:50 PM IST
Copy Link
Written by Shubhangi Gupta | Edited by Poulomi Ghosh, Hindustan Times, New Delhi

TN to become first in country to administer Covid shots to children over 2 years

Ma Subramanian said that once the Tamil Nadu state government gets the nod from the Centre regarding the inoculation of the vaccine, the state would be the first to do so.
52,379,870 doses of the vaccine have been administered in Tamil Nadu till 7am on Wednesday.(AP | Representational image)
52,379,870 doses of the vaccine have been administered in Tamil Nadu till 7am on Wednesday.(AP | Representational image)
Published on Oct 13, 2021 10:07 PM IST
Copy Link
Written by Srivatsan K C | Edited by Poulomi Ghosh, Hindustan Times, New Delhi

WHO to take final decision on Covaxin nod next week

The approval could greatly influence how other countries treat people vaccinated with Covaxin manufactured by Bharat Biotech
A woman receives a dose of Covaxin manufactured by Bharat Biotech (REUTERS)
A woman receives a dose of Covaxin manufactured by Bharat Biotech (REUTERS)
Updated on Oct 06, 2021 02:49 AM IST
Copy Link
ByRhythma Kaul, Hindustan Times, New Delhi

Bharat Biotech submits data from Covaxin's trials on children to DCGI: Report

The Hyderabad-based firm, last month, completed the jab's phase 2/3 trials for kids.
Bharat Biotech International Limited's Covaxin (HT File Photo)
Bharat Biotech International Limited's Covaxin (HT File Photo)
Published on Oct 03, 2021 10:24 AM IST
Copy Link
Byhindustantimes.com | Written by Karan Manral, New Delhi

‘Next 6-8 weeks are important as…’: Guleria on how Covid cases can drop

AIIMS director Dr Randeep Guleria said that he is hopeful Covaxin will soon be able to receive the WHO nod and travelling overseas will become easier for those who have taken both shots of the coronavirus vaccine.
AIIMS director Dr Randeep Guleria said that he is “hopeful” the approval of Covaxin by the WHO should happen soon. (ANI Photo)
AIIMS director Dr Randeep Guleria said that he is “hopeful” the approval of Covaxin by the WHO should happen soon. (ANI Photo)
Updated on Oct 01, 2021 06:26 PM IST
Copy Link
Written by Sharangee Dutta | Edited by Poulomi Ghosh, Hindustan Times, New Delhi

Working with WHO to get emergency use listing for Covaxin: Bharat Biotech

  • The company was responding to reports that said the grant of EUL could be delayed further as WHO had more technical queries regarding the inactivated whole virus vaccine.
Bharat Biotech is working with the World Health Organization (WHO) to obtain Emergency Use Listing for Covaxin, its Covid vaccine. (PTI)
Bharat Biotech is working with the World Health Organization (WHO) to obtain Emergency Use Listing for Covaxin, its Covid vaccine. (PTI)
Updated on Sep 29, 2021 03:13 AM IST
Copy Link
ByRhythma Kaul, New Delhi

‘Diligently working with WHO to obtain EUL at the earliest’, says Bharat Biotech

“As a responsible manufacturer with past approvals for our other vaccines, we do not find it appropriate to speculate or comment on the regulatory approval process and its timelines. We are diligently working with the WHO to obtain EUL at the earliest,” Bharat Biotech said.
Covaxin is one among the three vaccines being used in India's immunisation programme against Covid-19.(AP )
Covaxin is one among the three vaccines being used in India's immunisation programme against Covid-19.(AP )
Published on Sep 28, 2021 04:17 PM IST
Copy Link
Written by Srivatsan K C | Edited by Avik Roy, Hindustan Times, New Delhi

Bharat Biotech completes phase 2/3 trials of Covaxin in children

“Paediatric Covaxin just completed phase 2/3 trials. The data analysis is going on. We will be submitting the data by next week,” Bharat Biotech’s chairman and managing director Krishna Ella said.
Briefing on the production of Covaxin, Krishna Ella said that it would reach 55 million doses in October.(AP)
Briefing on the production of Covaxin, Krishna Ella said that it would reach 55 million doses in October.(AP)
Published on Sep 21, 2021 04:19 PM IST
Copy Link
Written by Srivatsan K C | Edited by Avik Roy, Hindustan Times, New Delhi
SHARE
  • 1
  • 2
  • 3
  • ...
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, December 09, 2021